Nonalcoholic fatty liver disease

Adolescent Medicine Clinics

Volumn 15, Issue 1, 2004, Pages 159-173

  Jonas, Maureen M ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ACETYLSALICYLIC ACID; AMIODARONE; CYCLINE; DIDANOSINE; ESTROGEN; GLUCOCORTICOID; ISONIAZID; PROTEIN DERIVATIVE; VALPROIC ACID;

ADOLESCENT; BODY MASS; CLINICAL FEATURE; COMPARATIVE STUDY; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; EPIDEMIC; FATTY LIVER; HISTOLOGY; HUMAN; LABORATORY TEST; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PHYSICAL EXAMINATION; PREVALENCE; REVIEW; RISK FACTOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE; UNITED STATES;

EID: 3142661087     PISSN: 15473368     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.admecli.2003.11.010     Document Type: Review

References (64)

1. Kim WR, Brown RSJ, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002;36:227-42.
2. Pietrobelli A, Faith MS, Allison DB, Gallagher D, Chiumello G, Heymsfield SB. Body mass index as a measure of adiposity among children and adolescents: a validation study. J Pediatr 1998;132:204-10.
3. Kimm SY, Barton BA, Obarzanek E, et al. Obesity development during adolescence in a biracial cohort: the NHLBI Growth and Health Study. Pediatrics 2002;110(5):e54.
4. Kimm SY, Glynn NW, Kriska AM, et al. Decline in physical activity in black girls and white girls during adolescence. N Engl J Med 2002;347:709-15.
5. Whitaker RC, Pepe MS, Wright JA, et al. Early adiposity rebound and the risk of adult obesity. Pediatrics 1998;101(3):E5.
6. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
7. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
8. Dwyer T, Blizzard L, Venn A, et al. Syndrome X in 8-year-old Australian children: stronger associations with current body fatness than with infant size or growth. Int J Obes Relat Metab Disord 2002;26:1301-9.
9. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-5.
10. Kawasaki T, Hashimoto N, Kikuchi T, et al. The relationship between fatty liver and hyperinsulinemia in obese Japanese children. J Pediatr Gastroenterol Nutr 1997;24:317-21.
11. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9.
12. Diehl AM. Nonalcoholic steatohepatitis. Semin Liv Dis 1999;19:221-9.
13. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liv Dis 2001;21:17-26.
14. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001;121:710-23.
15. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, et al. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 1995;127:700-4.
16. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. Am J Gastroenterol 1991;94:2467-74.
17. Wanless IR, Lentz J. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106-10.
18. Daniel S, Ben-Menachem T, Vasudevan G, et al. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999;94:3010-4.
19. Strauss RS, Barlow SE, Dietz WH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr 2000;136:727-33.
20. Kinugasa A, Tsunamoto K, Furukawa N, et al. Fatty liver and its fibrous changes found in simple obesity of children. J Pediatr Gastroenterol Nutr 1984;3:408-14.
21. Tazawa NH, Nishinomiya F, Takada G. Serum alanine aminotransferase activity in obese children. Acta Paediatr 1997;86:238-41.
22. Franzese A, Vajro P, Argenziano A, et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997;42:1428-32.
23. Fishbein MH, Miner M, Mogren C, Chalekson J. The spectrum of fatty liver in obese children and the relationship of serum aminotransferases to severity of steatosis. J Pediatr Gastroenterol Nutr 2003;36:54-61.
24. Tominaga K, Kurata JH, Chen YK, et al. Prevalence of fatty liver in Japanese children and relationship to obesity. Dig Dis Sci 1995;40:2002-9.
25. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-92.
26. Wilner IR, Waters B, Patil SR, et al. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001;96:2957-61.
27. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.
28. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-76.
29. Leclercq I, Farrell G, Field J, et al. YP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000;105:1067-75.
30. Haines N, Baker A, Boyer J, et al. Prognostic indicators of hepatic injury following jejunoileal bypass performed for refractory obesity: a prospective study. Hepatology 1981;1:161-5.
31. Cortez-Pinto H, Chatham J, Chacko V, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis. JAMA 1999;282:1659-64.
32. Garcia-Monzón C, Martin-Perez E, Iacono OL, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000;33:716-24.
33. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-23.
34. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-9.
35. Powell EE, Cooksley WGE, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80.
36. Moran JR, Ghishan FK, Halter SA, Greene HL. Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol 1983;78:374-7.
37. Sanyal AJ. Non-alcoholic steatohepatitis. Clin Perspect Gastroenterol 2000;2000:129-39.
38. Nakao K, Nakata K, Ohtsubo N, et al. Association between nonalcoholic fatty liver, markers of obesity, and serum leptin levels in young adults. Am J Gastroenterol 2002;97:1796-801.
39. Becker U, Deis A, Sorensen TI, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996;23:1025-9.
40. Teli MR, James OF, Burt AD, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995;22:1714-9.
41. Brolin RE, Bradley LJ, Taliwal RV. Unsuspected cirrhosis discovered during obesity operations. Arch Surg 1998;133:84-8.
42. Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-9.
43. Caldwell SH, Hespenheide EE. Subacute liver failure in obese women. Am J Gastroenterol 2002;97:2058-62.
44. Shimada M, Hashimoto E, Taniai M, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Hepatol 2002;37:154-60.
45. Manton ND, Lipsett J, Moore DJ, et al. Non-alcoholic steatohepatitis in children and adolescents. Med J Aust 2000;173:476-9.
46. Schwimmer JB, Deutsch R, Behling C, et al. Clinicopathological correlation of pediatric nonalcoholic fatty liver disease (NAFLD) [abstract]. Hepatology 2002;36:382A.
47. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000;30:48-53.
48. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 1999;30:1356-62.
49. Wabitsch M, Blum WF, Muche R, et al. Contribution of androgens to the gender differences in leptin production in obese children and adolescents. J Clin Invest 1997;100:808-13.
50. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990;99:1408-13.
51. Vajro P, Fontanella A, Perna C, et al. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994;125:239-41.
52. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-7.
53. Andersen T, Gluud C, Franzmann MB, et al. Hepatic effects of dietary weight loss in morbidly obese patients. J Hepatol 1991;12:224-9.
54. Rozental P, Biava C, Spencer H, Zimmerman HJ, et al. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 1967;12:198-208.
55. Ceriani R, Bunati S, Morini L, et al. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis [abstract]. Hepatology 1998;28:386A.
56. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996;23:1464-7.
57. Vajro P, Franzese A, Valerio B, et al. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 2000;136:739-43.
58. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999;31:384.
59. Abdelmalek MF, Angulo P, Jorgensen RA, et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001;96:2711-7.
60. Gulbahar O, Karasu AA, Ersoz G, et al. Treatment of nonalcoholic steatohepatitis with N-acetylcysteine [abstract]. Gastroenterology 2000;118:A1444.
61. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study. J Pediatr 2000;136:734-8.
62. Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-25.
63. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001;358:893-4.
64. Lin H, Yang S, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptindeficient mice. Nat Med 2000;6:998-1003.